LOS ANGELES--(BUSINESS WIRE)--
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Sanofi (the “Company”) (GCVRZ) concerning possible violations of federal securities laws. The investigation is related to certain statements issued by Sanofi concerning the Company’s business and financial prospects.
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at firstname.lastname@example.org to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Sanofi is a global healthcare company engaged in the research, development, manufacture and marketing of healthcare products, including pharmaceuticals and vaccines. The Company’s multiple sclerosis therapy Lemtrada™ (alemtuzumab) has completed two Phase III clinical studies and is under review for marketing approval in the U.S. and Europe. The investigation is related to a report prepared ahead of a U.S. Food and Drug Administration advisory panel meeting that the drug’s risks, which can make the body more vulnerable to other diseases, might be too great to justify approval.
According to a report published by Reuters on November 8, 2013, the FDA staff review noted “serious and potentially fatal” risks of autoimmune diseases including “blood disorders, infections and cancer.” The FDA staff did not recommend approval of Lemtrada “unless substantial clinical benefit exists.” Following this news, Sanofi stock dropped more than 60%, to a closing price of $0.77 per share on November 8, 2013, on extremely heavy trading volume.
If you purchased shares of Sanofi, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
- Health Care Industry